We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Advanced Instruments Appoints New CEO

By LabMedica International staff writers
Posted on 17 May 2017
Advanced Instruments, LLC, which designs, manufactures, and markets instrumentation and associated consumables for clinical, pharmaceutical, biotechnology, microbiology and dairy laboratories, has announced the appointment of Byron Selman as Chief Executive Officer. Mr. Selman replaces John Coughlin, who served as CEO of Advanced Instruments for over 16 years, and will continue in his retirement as a non-executive Member of the Board.

Mr. Selman brings with him a broad range of experience across multiple functional disciplines including sales, marketing, business development, engineering, operations, and general management. He joins Advanced Instruments after serving as President of Global Markets with Haemonetics Corporation, prior to which he spent over 20 years with Pall Corporation in various executive level and general management positions. Selman holds a Bachelor of Science degree in Mechanical Engineering from Case Western Reserve University, and a Master of Business Administration degree from the Frank G. Zarb School of Business at Hofstra University.

“We are excited to have Byron join Advanced Instruments,” said Craig Majernik, Managing Director at Windjammer Capital Investors, which acquired the company in October 2016. “His proven leadership abilities and demonstrated record of success position him well to lead the execution of the company’s organic and acquisition growth strategy.”

Selman said, “Advanced Instruments represents a unique opportunity, given its well-respected brand, technical know-how, and channels to market. I am encouraged by the multiple avenues available to the company to enhance and expand its well-established platform in the clinical diagnostic and biopharmaceutical tools markets.”


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
New
Drug Test Kit
DrugCheck 3000

Latest Industry News

Lunit and Microsoft Collaborate to Advance AI-Driven Cancer Diagnosis
17 May 2017  |   Industry

AMP Releases Best Practice Recommendations to Guide Clinical Laboratories Offering HRD Testing
17 May 2017  |   Industry

Illumina Acquires SomaLogic to Accelerate Proteomics Business
17 May 2017  |   Industry



PURITAN MEDICAL